In our trial, T-DM1 was effective for treating HER2-positive breast cancer after the failure of pyrotinib and/or trastuzumab plus pertuzumab, with an ORR of 47.2% and a manageable toxicity profile. This evidence concerns the gene ERBB2 and breast carcinoma.